Healthcare

Economic Bottlenecks: Overcoming Obstacles in Healthcare.

On this page

Pharmaceuticals and Chemicals in Transition: Protecting Profitability, Unlocking Potential

Hospitals and rehabilitation clinics operate in a challenging environment. Profitable operations are becoming increasingly difficult. Our restructuring experts help you unlock new value creation opportunities and minimize subsequent risks.

Whether a church-run acute care hospital or a private rehabilitation facility: What unites these institutions is not only increasing price and competitive pressure but also chronic underfunding. Most attempts to improve the economic situation fail due to the heterogeneous ownership structure. Meanwhile, one in every four facilities is fighting for survival. The situation in care facilities has also been increasingly tense for years.

What's crucial now is an unsparing look at the numbers. If the company's results are negative, restructuring must start as soon as possible: operationally, but also in terms of the balance sheet capital structures. Our methods for improving earnings and liquidity are proven. Above all, they are effective quickly.

With us, you have a partner by your side that isn't easily unsettled by a crisis.

The framework conditions in healthcare are pushing economic viability to its limits.
Uwe Köstens, Founder and Managing Partner, Head of Real EstateUwe Köstens, Founder and Managing Partner, Head of Real Estate View Uwe Kösten´s Profile

Our Service

Strategy & Corporate Performance

We help you refine your strategic priorities, tap into growth potential, and boost profitability and operational performance. Together, we create a solid foundation for decision-making, translate it into clear actions, and consistently implement changes in your organization, processes, and management systems.

To the section

Latest Perspectives on Healthcare

Dass sich die Krise erst jetzt, knapp drei Jahre nach Ausbruch der Pandemie, in Bilanz, GuV und Cashflow der Unternehmen bemerkbar macht, ist auch auf die nach wie vor gestörten Lieferketten zurückzuführen. Materialknappheit und fehlende oder immer teurere Transportkapazitäten vor allem aus Asien beeinträchtigen den Zufluss von Produkten und Teilen. Um in dieser Situation eine verlässliche Warenversorgung sicherzustellen, haben viele Unternehmen große Sicherheitsbestände aufgebaut. Auch das bindet ordentlich Liquidität.

Dr. Stefan Frings

Uwe Köstens, Gründungspartner von enomyc

The global economy is struggling hard with Covids consequences as the pandemic moves through its third year. What’s more the crisis mountain of supply chain stoppages, material and personnel shortages continues to grow: high energy and material costs are looming. In addition to all of this, cyber-attacks have now thrust forward, advancing to become our next big challenge. "A toxic cocktail," is how Uwe Köstens, founding partner of enomyc, sums up the situation. Crisis is his business: he has been advising on SME issues for more than 22 years. As a result, he is very knowledgeable about the effects crises have on the global economy. But what makes the current situation so dangerous? What in particular puts the eye on red alert? And how on earth can companies manage a less bumpy landing in the new reality called "crisis"? An interview.

Despina Borelidis

Konsequent und ganzheitlich restrukturieren mit Dr. Stefan Frings

In recent months, many small and medium-sized enterprises (SMEs) have faced existential crises due to challenging economic conditions, the unique structural situation in Germany, and the lasting effects of the COVID-19 pandemic. The situation has been further exacerbated by sharply rising capital costs, increased risk aversion among financiers, and repayment obligations from the pandemic period. According to enomyc author Dr. Stefan Frings, these multiple crises present the perfect opportunity for decisive and consistent action. Often, it takes significant pressure before stakeholders are willing to confront harsh realities and, with careful consideration, bring an end to long-standing but unsustainable practices.

Dr. Stefan Frings

Strategy & Corporate Performance

Big Data: How companies make their data talk

It’s a horror scenario for any company: losing one your highest-revenue customers. The management wants to know how the loss will affect the operating result. The consequences for turnover, inventory, material and personnel costs also need to be identified as quickly as possible. In theory, this is the time for management control. In practice, however, this is often hopelessly overwhelmed. In his article, enomyc author Peter Kink describes how companies can quickly gain an overview with targeted mass data analysis. And why, despite everything, corporate management remains a managerial domain.

Peter Kink-Katthöfer

The Corona pandemic and its consequences, including disruption of important supply chains and shortages of materials, have plunged many companies into a crisis that threatens their very existence. Small and medium-sized companies in particular are having to contend with double-digit falls in sales and earnings. Companies that failed to prepare for the crisis in good times have been hit particularly hard. So it's high time to tackle the issue of preventive restructuring now. In particular, products with an insufficient contribution to earnings, inefficient processes and cumbersome decision-making structures often lead to problems: While they can still be compensated for in good economic times, they can quickly become a threat to the company's existence in a crisis. In this situation, companies that see the crisis as an opportunity to anticipate necessary changes and implement them quickly have a clear advantage. The goal is to improve effectiveness, increase efficiency, launch growth initiatives and increase liquidity . The necessary measures should be taken proactively, quickly and thoroughly before liquidity bottlenecks force the company even further into the defensive. The first essential prerequisite to get back on the road to success is an unsparing look at the actual situation of the company with all its strengths, weaknesses, opportunities and risks.

Dr. Stefan Frings

Christian Zeller, Partner enomyc und Head of Operations

Strategy & Corporate Performance

How is the MedTech Industry Really Doing?

At first glance, the German MedTech industry seems to be doing well. It appears resilient in crises, innovative, strong in exports, and optimistic. However, on a global scale, its business growth seems to have slowed. What’s troubling the MedTech industry? How is its innovative strength holding up? And what about its future? enomyc, in collaboration with the German industry association SPECTARIS, which focuses on optics, photonics, analytical, and medical technology, surveyed over 40 companies in the industry. In this expert interview with Christian Zeller, we explore the sentiment, strengths, and levers of the German MedTech industry.

Despina Borelidis

Selected Healthcare Experts